Table of Contents
BALTIMORE — Lupin announced the launch of minocycline hydrochloride extended-release tablets USP 55mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s minocycline hydrochloride ER tablets USP 55mg is a generic version of Medicis Pharmaceutical Corporation’s Solodyn 55 mg. It is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
Minocycline Hydrochloride ER Tablets USP, 55 mg (RLD: Solodyn) had annual sales of approximately USD 76.8 million in the US (IQVIA MAT December 2018).
